A Problem-Solving Therapy With Apple Watch Support for College Students With Alcohol Use Disorder Symptoms: Pilot Randomized Controlled Trial.

JMIR Form ResOct 5, 2026 (epub)
Clinical ResearchPsychiatry

Hagar Hallihan, Sangeun Lee, Ruth Adomah et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the feasibility and preliminary effectiveness of a problem-solving therapy supported by Apple Watch (PST-APPLE) for college students with alcohol use disorder (AUD) symptoms. Among 26 participants, the intervention group showed significant reductions in alcohol misuse, with a mean difference of -4.70 in AUDIT scores compared to the control group.

Key findings

  • The intervention group had a mean difference of -4.70 in AUDIT scores compared to the control group.
  • Social motivation scores decreased by a mean difference of -0.85 in the intervention group.
  • Enhancement motivation scores also decreased by a mean difference of -0.75 in the intervention group.

Why it matters

Addressing alcohol use disorder in college students is crucial due to its prevalence and associated health risks. Innovative interventions like PST-APPLE may enhance treatment engagement and effectiveness, potentially improving outcomes in this vulnerable population.

Source

PubMed · PMID 42832266

Published in JMIR Form Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.